Rescuing Research Participants After Alzheimer Trials Stop Early

Jason Karlawish, MD and Emily Largent, PhD from the IMPACT Collaboratory Regulation and Ethics Core wrote an editorial reflecting on the unique ethical complexities around telling participants in an Alzheimer’s drug study that the study had abruptly ended. The story was also covered in the New York Times.

Click here to read the full JAMA Neurology editorial

Click here to read the article in the New York Times